PP-147 Impact of gender on virologic responses rates in genotype 1 chronic hepatitis C patients with peginterferon alfa-2a and ribavirin treatment
0
Citation
0
Reference
10
Related Paper
Keywords:
Peginterferon alfa-2a
Topics:
Peginterferon alfa-2a
Hepatitis C
Cite
Citations (0)
Peginterferon alfa-2a
Cite
Citations (1)
Hepatitis C
Interferon alfa
Cite
Citations (2)
Objective: To assess the efficacy of combination therapy of Conventional interferon alpha-2b plus ribavirin in patients of chronic hepatitis C.
Methods: Records of 65 patients (43 males and 22 females) of chronic hepatitis C treated with combination therapy of interferon alpha-2b plus ribavirin from January 2003 to December 2003 were analyzed for base-line parameters, response rates and any adverse effects.
Results: End-treatment response was found in 86.04% male patients and 86.36% female patients. Sustained response was found in 81.39% male patients and 86.36% female patients.
Conclusions: The study shows that conventional interferon plus ribavirin combination therapy remains an effective therapy in the treatment of chronic hepatitis C naive patients in our set-up. (Rawal Med J 2005;30:9-11).
Combination therapy
Hepatitis C
Cite
Citations (13)
Peginterferon alfa-2a
Cite
Citations (0)
Peginterferon alfa-2a
Cite
Citations (0)
Peginterferon alfa-2a
Interferon alfa
Cite
Citations (1)
Summary Background Peginterferon alfa‐2a/ribavirin treatment resulted in fewer incidences of depression and flu‐like symptoms than that of standard interferon/ribavirin, whereas peginterferon alfa‐2b/ribavirin and standard interferon/ribavirin treatment resulted in similar incidences of these adverse events (AEs). Aim To assess the efficacy and safety of peginterferon alfa‐2a/ribavirin in genotype 1‐infected patients treated for up to 12 weeks with peginterferon alfa‐2b/ribavirin but not achieving early virologic response (EVR) (non‐EVR) or nontolerant (NT) because of depression, fatigue, flu‐like symptoms, or injection‐site reactions. Methods Nontolerants were treated for an additional 36 weeks and non‐EVRs for an additional 60 weeks with peginterferon alfa‐2a (180 μg/week)/ribavirin (1000/1200 mg/day). Patients with detectable HCV RNA after 12 weeks were discontinued. Results Of 25 NTs, 23 (92%) were HCV‐RNA negative after 12 weeks on peginterferon alfa‐2a/ribavirin and 14 (56%) achieved sustained virologic response. Of 32 non‐EVRs to peginterferon alfa‐2b/ribavirin, four (13%) achieved EVR with peginterferon alfa‐2a/ribavirin and one (3%) achieved sustained virologic response. Four non‐EVRs and 0 NTs were withdrawn for AEs; 26 (81%) and 24 (96%), respectively, completed peginterferon alfa‐2a/ribavirin treatment or were withdrawn for insufficient response at week 12. In NTs, depression, fatigue, flu‐like symptoms, and injection‐site reactions declined during treatment. Conclusion Most patients who did not tolerate peginterferon alfa‐2b/ribavirin because of AEs, and who completed the full 36‐week course of peginterferon alfa‐2a/ribavirin treatment, achieved sustained virologic response.
Peginterferon alfa-2a
Hepatitis C
Interferon alfa
Cite
Citations (7)
Tolerability
Hepatitis C
Cite
Citations (0)
Peginterferon alfa-2a
Cite
Citations (1)